ArticleThe journal of allergy and clinical immunology. Global2026
Asthma biologic effectiveness by age and sex in the US CHRONICLE study.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologic therapies are effective in reducing asthma exacerbations in patients with severe asthma; however, the impact of age and sex on the real-world effectiveness of these therapies is not well understood. Objective: Our aim was to examine real-world outcomes before and after biologic initiation among adults with severe asthma, stratified by age and sex. Methods: CHRONICLE was an observational study of subspecialist-treated US adults with severe asthma. Eligible patients included those receiving maintenance systemic corticosteroids or other systemic immunosuppressants or those patients whose asthma was uncontrolled despite receiving high-dosage inhaled corticosteroids and additional controllers. Asthma exacerbation rates were compared 6 months before and 6 months after biologic initiation in patients stratified by age and sex. To enable a self-controlled analysis, the included patients had no biologic use during the preinitiation period. Results: Of the 800 patients (549 female and 251 male) who started treatment with a biologic and had complete data for at least 6 months before and 6 months after initiation, 294 were aged 18 to 49 years, 314 were aged 50 to 64 years, and 192 were aged 65 years or older. Across the different biologic therapies evaluated, the reductions in exacerbation rate ranged from 37% to 63% among patients aged 18 to 49 years, 44% to 52% in patients aged 50 to 64 years, 56% to 63% among patients aged 65 years or older, 34% to 66% in males, and 46% to 62% in females. Conclusion: Biologic therapies reduce asthma exacerbations in adults with severe asthma, regardless of age or sex. These findings support the use of biologics in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.